Pipeline

Pipeline Overview

We are assembling a robust portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematologic malignancies. All of our product candidates incorporate our proprietary Allo-Evasion™ technology to avoid host rejection and potentially increase the durability of clinical responses.
Product iPSC Platform Targets Indications Discovery Preclinical Clinical Collaborator
CNTY-101 READ MORE CLOSE

CNTY-101: Our lead candidate targeting CD19 for relapsed, refractory B-cell lymphoma
CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch. CNTY-101 is currently being evaluated in a Phase 1 ELiPSE-1 trial for relapsed or refractory CD19 positive B-cell lymphomas.

iNK
CD19
B-Cell Malignancies

CNTY-101: Our lead candidate targeting CD19 for relapsed, refractory B-cell lymphoma
CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch. CNTY-101 is currently being evaluated in a Phase 1 ELiPSE-1 trial for relapsed or refractory CD19 positive B-cell lymphomas.

CNTY-102 READ MORE CLOSE

CNTY-102: The Company has selected targets for CNTY-102, a CAR-iT product candidate, against CD19 and CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-102 will simultaneously target CD19 and CD22, intended to increase depth and durability of response by eliminating the effect of CD19 antigen loss that has been observed as a factor limiting treatment durability, as well as targeting CD22, an independently regulated, ubiquitous and validated B-cell target. We have elected to develop CNTY-102 on our gamma delta iT platform.

iT
CD19 + CD22
B-Cell Malignancies

CNTY-102: The Company has selected targets for CNTY-102, a CAR-iT product candidate, against CD19 and CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-102 will simultaneously target CD19 and CD22, intended to increase depth and durability of response by eliminating the effect of CD19 antigen loss that has been observed as a factor limiting treatment durability, as well as targeting CD22, an independently regulated, ubiquitous and validated B-cell target. We have elected to develop CNTY-102 on our gamma delta iT platform.

CNTY-107 READ MORE CLOSE

CNTY-107: Our γδ iT product candidate for the treatment of solid tumors expressing Nectin-4.

iT
Nectin-4
Solid Tumors

CNTY-107: Our γδ iT product candidate for the treatment of solid tumors expressing Nectin-4.

CNTY-104 READ MORE CLOSE

CNTY-104: CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia
Under our collaboration with Bristol Myers Squibb, CNTY-104 will utilize our multi-specific iNK or iT cells for the treatment of AML.

iNK /iT
Multi-specific
Acute Myeloid Leukemia

CNTY-104: CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia
Under our collaboration with Bristol Myers Squibb, CNTY-104 will utilize our multi-specific iNK or iT cells for the treatment of AML.

CNTY-106 READ MORE CLOSE

CNTY-106: CAR-iT or CAR-iNK multi-specific candidate for multiple myeloma
Under our collaboration with Bristol Myers Squibb, CNTY-106 will utilize our multi-specific iNK or iT cells for the treatment of multiple myeloma.

iNK /iT
Multi-specific
Multiple Myeloma

CNTY-106: CAR-iT or CAR-iNK multi-specific candidate for multiple myeloma
Under our collaboration with Bristol Myers Squibb, CNTY-106 will utilize our multi-specific iNK or iT cells for the treatment of multiple myeloma.

Discovery READ MORE CLOSE
iNK /iT
TBD
Hematological / Solid Tumors

Solid Tumors

Hematologic Tumors